Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biohaven Pharmaceutical Holding Co Ltd

BHVN
Current price
44.39 USD -4.27 USD (-8.78%)
Last closed 48.66 USD
ISIN VGG111961055
Sector Healthcare
Industry Biotechnology
Exchange NYSE
Capitalization 5 397 903 360 USD
Yield for 12 month +47.52 %
1Y
3Y
5Y
10Y
15Y
BHVN
21.11.2021 - 28.11.2021

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. Address: 215 Church Street, New Haven, CT, United States, 06510

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

65.23 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-3 369 000 USD

Last Year

-1 386 000 USD

Current Quarter

-977 000 USD

Last Quarter

-941 000 USD

Key Figures BHVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -774 438 016 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -89.65 %
PEG Ratio
Return On Equity TTM -193.67 %
Wall Street Target Price 65.23 USD
Revenue TTM
Book Value 4.16 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -9.3 USD
Diluted Eps TTM -9.3 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BHVN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BHVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BHVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.1877
Price Book MRQ 14.0665

Financials BHVN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BHVN

For 52 weeks

26.8 USD 62.21 USD
50 Day MA 47.05 USD
Shares Short Prior Month 9 986 800
200 Day MA 43.65 USD
Short Ratio 6.25
Shares Short 9 329 900
Short Percent 10.38 %